IOL Chemicals IOL Chemicals

X
[{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carmell Therapeutics Receives IND Clearance for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp.","pharmaFlowCategory":"D","amount":"$154.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Axolotl Biologix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Axolotl Biologix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Axolotl Biologix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Axolotl Biologix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Carmell Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

            Lead Product(s): Axolotl Graft

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Recipient: Axolotl Biologix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger September 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

            Lead Product(s): Axolotl Graft

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Axolotl Biologix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger September 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

            Lead Product(s): Axolotl Graft

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Axolotl Biologix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger August 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

            Lead Product(s): Axolotl Graft

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Axolotl Biologix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger July 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Carmell Therapeutics is in early preclinical testing of BHA product as an orthobiolgoic to determine the capability of BHA to act as an enhancer to existing bone graft substitutes as well as a stand-alone new alternative to bone graft substitute products.

            Lead Product(s): Allogeneic Plasma-based Biomaterial,Calcium Phosphate

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BHA

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alpha Healthcare Acquisition Corp.

            Deal Size: $154.0 million Upfront Cash: Undisclosed

            Deal Type: Merger January 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.

            Lead Product(s): Calcium Phosphate,Blood-derived component

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.

            Lead Product(s): Calcium Phosphate

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY